As you may have heard, the drugs watchdog NICE has given a preliminary `no' to abiraterone, a new prostate cancer drug, because the manufacturers have set the price too high. We hope that the situation can be changed, but we're frustrated that this situation has been allowed to happen.
Since it became available last year, abiraterone has become one of the most requested drugs on the NHS. Both patients and doctors alike value the extra months it gives men with their families, if their prostate cancer comes back after chemotherapy.
Cancer Research UK played a key role in this drug's development, from pioneering lab work, through pre-clinical studies, all the way up to early patient trials. Find out why, and how we helped develop the drug, in the video and on our blog, and please do let us know what YOU think